Moscow, May 16,2013. Today several countries have regulatory requirements in place for the development and evaluation of biotherapeutic and biosimilar medicines. The European Union, for example, provides unified standards and guidelines that are effective in the entire region. In Russia, on the contrary, these topics are not yet regulated. This is one of the key points that international and Russian experts are discussing in the context of the two-day workshop Biotherapeutic Medicines – Regulatory Challenges and Current Practices. Approaches for Harmonization.
April 1, 2013, Moscow – The Association of International Pharmaceutical Manufacturers announces extension of the Association member list. On March 27, 2013 the General Meeting of AIPM members decided on the membership of R-Pharm Group. It is an important achievement for the Russian pharmaceutical market confirming the inconvertibility of partnership between Russian and international pharmaceutical companies and their further integration.
Draft documents limiting the state purchases of foreign medication do not take into account the Russian Federation citizens’ rights for affordable and high-quality treatment. It has been announced by the participants of the press conference devoted to the discussion on the draft RF Government Decree “On introducing additional requirements to order placement participants in case of placing orders for the provision of medications" and draft Law prepared by the Ministry of Industry and Trade of Russia and devoted to the criteria in accordance to which medications can be attributed to medicinal products of the Russian origin.
The world-famous Prix Galien Prize, created in France in 1970, is the most prestigious prize in biotechnologies and the pharmaceutical industry, which is annually awarded for outstanding achievements in the development of innovative treatment methods and technologies. The Galien Foundation has now decided to include Russia in the list of host countries for the competition, beginning from 2013.
25 April 2012, Moscow. – The Institute of Legislation and Comparative Law under the Government of the Russian Federation presented Legal Opinion on the topic ‘Legal Aspects of Interaction between Pharmaceutical Company Representatives and Healthcare Professionals’. This Legal Opinion was prepared with the support of the Association of International Pharmaceutical Manufacturers (AIPM).
On March 19, 2012, Pharmatsevtichenskiy vestnik (Pharmaceutical bulletin) newspaper and “Pharmexpert” Market Research Centre announced the most influential entities of the Russian pharmaceutical market in 2011. The annual review, which has been conducted more than 10 years, surveys independent market experts across various areas to rank influence in the Russian healthcare industry. Based on the answers provided by peers and industry experts, AIPM was named the Most Influential Non-Profit and Public Association by a wide margin.
All over the world February, 29 was marked as International Rare Disease Day - when the organizations active in the field of rare diseases and their partners join forces to raise awareness of society on problems of millions of people living with orphan diseases. Association of International Pharmaceutical Manufacturers (AIPM) partners with the international non-governmental patient-driven alliance EURORDIS and contributes to the communication to the Russian patients, doctors, and other stakeholders with the Russian version of web resource www.eurordis.org/ru
MOSCOW, November 1, 2011 The Association of International Pharmaceutical Manufacturers (AIPM) actively participates in the work of “The Council of Europe Convention on Counterfeiting of Medical Products and Similar Crimes Involving Threats to Public Health (Medicrime Convention)”, High Level International Conference held in Moscow on October 26 - 28, 2011.
May 17, 2011, Saint-Petersburg. Association of International Pharmaceutical Manufacturers (AIPM) believes that the introduction of the proposed wording of the Article 69 of the Federal law draft “On bases of health protection of citizens of the Russian Federation” can cause serious damage to Russian healthcare. This opinion was expressed during the Russian Pharmaceutical Forum of Adam Smith Institute.
The results of AIPM research show an insufficient level of diagnosis and low awareness of their personal health.
The Association of International Pharmaceutical Manufacturers (AIPM) supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) conducted a survey entitled Population Attitude to Personal Health: Perception of Health, Understanding of Risk Factors, Morbidity and Mortality in Russia. The findings will be presented on the eve of the WHO Global Forum: Addressing the Challenge of Non-communicable Diseases (NCD) and the First Global Ministerial Conference on Healthy Lifestyles and Non-communicable Disease Control, which will be held in Moscow on April 27, 28 and 29, 2011, under the auspices of the World Health Organization (WHO) and the Russian Federation.
Eisai, Galderma, Macleods and Takeda were admitted to membership in the Association of International Pharmaceutical Manufacturers (AIPM) at a General Meeting of Members of the Association.
Novartis AG is planning to build a 2-billion-units plant in the territory of a pharmaceutical cluster in Saint-Petersburg. The level of investment will make up 500 billion dollars within the next 5 years.
The National drug policy forum has been held in Moscow on December 10. Tatiana Golikova, Minister of Healthcare and Social Development, has presented the main legislation initiatives carried out in this field: the Public health protection law, the Biomedical technologies law, the Compulsory medical organizations' responsibility law. Mrs Golikova has also told about the Compulsory medical insurance law and the Regional health care programs which would cost about 460 billion dollars to the government.
According to the reports of press service of Ministry of Healthcare and Social Development the Register of Maximum Manufacture’s Selling Price for medicine, included into Essential Drug List is published on November 15.
Ministry of economic development of Russia has elaborated a socio-economic development forecast for Russian Federation in 2011 and also for 2012-2013 planned periods. The forecast includes the results of socio-economic development of Russian Federation from January to July 2010 and also information provided by executive bodies and Bank of Russia.
Information about actual limit pricing fixed by Russian and foreign pharmaceutical manufacturers is collected with the view of recalculation. All data received is published in Russian Health Inspectorate web-site (http://www.rznd.ru). Price without shipping and handling charges is published with no VAT metering. Information about the quantity of packs; manufacturing date; serial number and conformance certificate registration date is also included.
The Russian government has established the import rules for drugs intended for medical use, with the exception of drugs intended for human and emergency aiding. The rules do not apply to narcotics, psychotropic agents and their precursors
The Russian government has approved the Federal target program conception entitled "The Russian pharmaceutical and medical industry development for a period till 2020 and further perspective" on the 1st October 2010.
As a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), AIPM takes part in the 60th session of the WHO Regional Committee for Europe, taking place in Moscow, from 13 to 15 September.